Seeking Alpha

Antibacterial-drug developer Trius Therapeutics (TSRX -8.22%) slips after pricing a 6.3M share...

Antibacterial-drug developer Trius Therapeutics (TSRX -8.22%) slips after pricing a 6.3M share secondary offering at $4.75 a share, a 9% discount to yesterday's close. The company made the announcement late yesterday without any details as to its size or scope. TSRX has a market cap of around $213M with a 39.4M share float.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs